<DOC>
	<DOCNO>NCT02031302</DOCNO>
	<brief_summary>The purpose RESPOND post market study collect real world clinical device performance outcome data Lotus Valve System use routine clinical practice demonstrate commercially available Lotus Valve System safe effective treatment patient severe calcific aortic stenosis .</brief_summary>
	<brief_title>RESPOND Post Market Study</brief_title>
	<detailed_description>The RESPOND study prospective , open label , single arm , multi-center , observational post market study design collect real world clinical device performance outcome data commercially available Lotus Valve use routine clinical practice treatment severe calcific aortic stenosis . Approximately 1000 real-world , consecutive subject enrol 50 study center Europe , Asia Pacific Central/South America . All enrolled subject contact follow-up 30 day , 1 , 2 , 3 , 4 5 year post index valve implantation . Follow-up visit 1 year post valve implantation conduct via outpatient clinic visit . Follow-up visit 30 day 2 5 year may conduct person ( prefer ) via telephone interview . Subjects implant Lotus Valve follow safety 30 day initial attempted index procedure . Collection safety event include serious adverse event ( SAE ) lead death , serious adverse device effect ( SADE ) , adverse device effect ( ADE ) , unanticipated serious adverse device effect ( USADE ) , Valve Academic Research Consortium ( VARC ) event regardless seriousness device relationship 5 year follow-up . The RESPOND study conduct accordance International Organization Standardization ( ISO ) 14155 : 2011 ; ethical principle origins Declaration Helsinki ; relevant part International Conference Harmonization ( ICH ) Guidelines Good Clinical Practices ( GCP ) ; pertinent individual country/state/local law regulation . An additional cohort approximately 50 subject enrol 6 study center Europe enrollment main cohort complete assess center-driven implantation technique commercially available Lotus Valve Depth Guard technology .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Subjects evaluate eligibility clinical center 's heart team per local standard practice accordance Directions Use .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lotus</keyword>
	<keyword>Valve</keyword>
	<keyword>Real world</keyword>
	<keyword>Aortic stenosis</keyword>
	<keyword>High risk</keyword>
</DOC>